1-((2R,5S)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Catalog No. :
ACDQPS959
CAS No. :
1792180-79-0
Molecular Formula :
C15H19N5O
Molecular Weight :
285.35

IUPAC Name:1-((2R,5S)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

1-((2R,5S)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg99%$271.00Login to see priceInquiryInquiry
10mg99%$435.00Login to see priceInquiryInquiry
25mg99%$870.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-((2R,5S)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
IUPAC Name1-((2R,5S)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
Molecular FormulaC15H19N5O
Molecular Weight285.35
SMILESC=CC(N1[C@H](C)CC[C@H](NC2=C3C(NC=C3)=NC=N2)C1)=O
InChI KeyCBRJPFGIXUFMTM-MNOVXSKESA-N
Synonym1-((2R,5S)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one;2-Propen-1-one, 1-[(2R,5S)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-;(2R,5S)-Ritlecitinib;Ritlecitinib Impurity 13
CAS No.1792180-79-0

Synthetic Route by SureRoute

1. ACDQPS959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDQPS959 route product structure diagram
    ACDQPS9591792180-79-0
Inquiry

2. ACDQPS959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDQPS959 route product structure diagram
    ACDQPS9591792180-79-0
Inquiry

Comments (0)